Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results
2024 | 7 | 1 | 63-78

Article title

Advances in understanding, diagnosis and targeting ATTR cardiomyopathy: a review

Content

Title variants

Languages of publication

Abstracts

EN
Transthyretin amyloidosis (ATTR) manifests as wild-type (ATTRwt) and hereditary/mutant (ATTRv) forms and can lead to heart failure due to cardiac amyloidopathy. Diagnosing ATTR, particularly in asymptomatic carriers of pathogenic variants, remains challenging despite the advances. Complex and multi-aspect management involves a limited range of well-examined conventional therapies to address the heart failure and frequently coexisting arrhythmias and valvular issues. Disease-modifying treatment, RNA-based treatments, CRISPR-Cas9 gene editing and monoclonal antibodies targeting amyloid deposits are recent and promising innovations. This review explores the diagnostic intricacies, therapeutic dilemmas and emerging solutions in ATTR cardiomyopathy. The significance of early detection and precise, targeted approaches to enhance patient outcomes is underscored.

Year

Volume

7

Issue

1

Pages

63-78

Physical description

Dates

published
2024

Contributors

author
  • Faculty of Medicine, Medical University of Gdańsk, Poland
author
  • Lower Silesian Oncology Center, Wrocław, Poland
  • Orthopedic Clinic Rehasport, Gdańsk, Poland
author
  • T. Marciniak Memorial Lower Silesian Specialist Hospital, Wrocław, Poland

References

  • Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol [Internet]. 2015;24(6):343–50. Available from: https://linkinghub.elsevier.com/retrieve/pii/S105488071500085X.
  • ESC Cardiomyopathy and Myocarditis Registry [Internet]. [cited 2023 Oct 11]. Available from: https://www.escardio.org/Research/registries.
  • Rasmussen TB, Ladefoged BT, Dybro AM, Clemmensen TS, Sørensen RH, Terkelsen AJ, et al. Transthyretin Gene Variants and Associated Phenotypes in Danish Patients with Amyloid Cardiomyopathy. Cardiogenetics [Internet]. 2022;12(1):1–11. Available from: https://www.mdpi.com/2035-8148/12/1/1.
  • Migliaccio MG, Iodice F, Di Mauro M, Iannuzzi A, Pacileo R, Caiazza M, et al. Cardiac Amyloidosis: Diagnostic Tools for a Challenging Disease. Cardiogenetics [Internet]. 2021;11(3):111–21. Available from: https://www.mdpi.com/2035-8148/11/3/12.
  • Dubrey S. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM [Internet]. 1998;91(2):141–57. Available from: https://academic.oup.com/qjmed/article-lookup/doi/10.1093/qjmed/91.2.141.
  • Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR Amyloidosis: Current and Emerging Management Strategies. JACC CardioOncology [Internet]. 2021;3(4):488–505. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2666087321001551.
  • Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. N Engl J Med [Internet]. 2002;346(23):1786–91. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa013354.
  • Ihne S, Morbach C, Sommer C, Geier A, Knop S, Störk S. Amyloidosis - the Diagnosis and Treatment of an Underdiagnosed Disease. Dtsch Arztebl Int [Internet]. 2020; Available from: https://www.aerzteblatt.de/10.3238/arztebl.2020.0159.
  • Adams D, Ando Y, Beirão JM, Coelho T, Gertz MA, Gillmore JD, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol [Internet]. 2021;268(6):2109–22. Available from: https://link.springer.com/10.1007/s00415-019-09688-0.
  • Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, et al. Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans. N Engl J Med [Internet]. 1997;336(7):466–73. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM199702133360703.
  • Quarta CC, Buxbaum JN, Shah AM, Falk RH, Claggett B, Kitzman DW, et al. The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. N Engl J Med [Internet]. 2015;372(1):21–9. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1404852.
  • Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. J Am Coll Cardiol [Internet]. 2016;68(2):161–72. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109716330108.
  • Akinboboye O, Shah K, Warner AL, Damy T, Taylor HA, Gollob J, et al. DISCOVERY: prevalence of transthyretin ( TTR ) mutations in a US-centric patient population suspected of having cardiac amyloidosis. Amyloid [Internet]. 2020;27(4):223–30. Available from: https://www.tandfonline.com/doi/full/10.1080/13506129.2020.1764928.
  • Rowczenio D, Quarta CC, Fontana M, Whelan CJ, Martinez-Naharro A, Trojer H, et al. Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience. Hum Mutat [Internet]. 2019;40(1):90–6. Available from: https://onlinelibrary.wiley.com/doi/10.1002/humu.23669.
  • Iodice F, Di Mauro M, Migliaccio MG, Iannuzzi A, Pacileo R, Caiazza M, et al. Cardiac Amyloidosis Therapy: A Systematic Review. Cardiogenetics [Internet]. 2021;11(1):10–7. Available from: https://www.mdpi.com/2035-8148/11/1/2.
  • Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J [Internet]. 2018;39(30):2799–806. Available from: https://academic.oup.com/eurheartj/article/39/30/2799/4557556.
  • Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Hear Fail [Internet]. 2019;12(9). Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.119.006075.
  • Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol [Internet]. 2020;300:191–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167527319309350.
  • Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol [Internet]. 2021;77(2):128–39. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109720377354.
  • Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol [Internet]. 2011;42(11):1785–91. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0046817711001444.
  • Bhuiyan T, Helmke S, Patel AR, Ruberg FL, Packman J, Cheung K, et al. Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type Transthyretin. Circ Hear Fail [Internet]. 2011;4(2):121–8. Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.109.910455.
  • Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J [Internet]. 2020;41(14):1439–47. Available from: https://academic.oup.com/eurheartj/article/41/14/1439/5708960.
  • Sartiani L, Bucciantini M, Spinelli V, Leri M, Natalello A, Nosi D, et al. Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. Biophys J [Internet]. 2016;111(9):2024–38. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0006349516308037.
  • Giancaterino S, Urey MA, Darden D, Hsu JC. Management of Arrhythmias in Cardiac Amyloidosis. JACC Clin Electrophysiol [Internet]. 2020;6(4):351–61. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405500X20300797.
  • El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis. J Am Coll Cardiol [Internet]. 2019;73(5):589–97. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109718393914.
  • Donnellan E, Elshazly MB, Vakamudi S, Wazni OM, Cohen JA, Kanj M, et al. No Association Between CHADS-VASc Score and Left Atrial Appendage Thrombus in Patients With Transthyretin Amyloidosis. JACC Clin Electrophysiol [Internet]. 2019;5(12):1473–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405500X1930831X.
  • Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, et al. Intracardiac Thrombosis and Embolism in Patients With Cardiac Amyloidosis. Circulation [Internet]. 2007;116(21):2420–6. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.107.697763.
  • Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild‐type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Hear Fail [Internet]. 2018;5(5):772–9. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ehf2.12308.
  • Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. EP Eur [Internet]. 2020;22(2):259–64. Available from: https://academic.oup.com/europace/article/22/2/259/5625716.
  • Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W, et al. Atrial Fibrillation in Transthyretin Cardiac Amyloidosis. JACC Clin Electrophysiol [Internet]. 2020;6(9):1118–27. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405500X20303376.
  • Sanchis K, Cariou E, Colombat M, Ribes D, Huart A, Cintas P, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality. Amyloid [Internet]. 2019;26(3):128–38. Available from: https://www.tandfonline.com/doi/full/10.1080/13506129.2019.1620724.
  • Fernandes A, Caetano F, Almeida I, Paiva L, Gomes P, Mota P, et al. Diagnostic approach to cardiac amyloidosis: A case report. Rev Port Cardiol (English Ed [Internet]. 2016;35(5):305.e1-305.e7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S217420491630023X.
  • Algalarrondo V, Dinanian S, Juin C, Chemla D, Bennani SL, Sebag C, et al. Prophylactic pacemaker implantation in familial amyloid polyneuropathy. Hear Rhythm [Internet]. 2012;9(7):1069–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1547527112002019.
  • Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J [Internet]. 2021;42(35):3427–520. Available from: https://academic.oup.com/eurheartj/article/42/35/3427/6358547.
  • Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA. Cardiac Resynchronization Therapy for Transthyretin Cardiac Amyloidosis. J Am Heart Assoc [Internet]. 2020;9(14). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.120.017335.
  • Kristen A V., Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack F-U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Hear Rhythm [Internet]. 2008;5(2):235–40. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1547527107010260.
  • Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J [Internet]. 2015;36(41):2793–867. Available from: https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehv316.
  • Sławiński G, Dorniak K, Lewicka E. Implantable cardioverter-defibrillators in cardiac amyloidosis: a grey zone requiring an individual approach. Kardiol Pol [Internet]. 2020;78(9):934–6. Available from: https://journals.viamedica.pl/kardiologia_polska/article/view/82656.
  • Scully PR, Patel KP, Treibel TA, Thornton GD, Hughes RK, Chadalavada S, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J [Internet]. 2020;41(29):2759–67. Available from: https://academic.oup.com/eurheartj/article/41/29/2759/5817909.
  • Arana-Achaga X, Goena-Vives C, Villanueva-Benito I, Solla-Ruiz I, Rengel Jimenez A, Gaspar TI, et al. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis. JACC Cardiovasc Imaging [Internet]. 2023;16(12):1567–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X23002218.
  • Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med [Internet]. 2020;71(1):203–19. Available from: https://www.annualreviews.org/doi/10.1146/annurev-med-052918-020140.
  • Xu B, Godoy Rivas C, Rodriguez ER, Tan C, Gillinov AM, Harb S, et al. Unrecognized Cardiac Amyloidosis at the Time of Mitral Valve Surgery: Incidence and Outcomes. Cardiology [Internet]. 2019;142(4):253–8. Available from: https://karger.com/CRD/article/doi/10.1159/000499933.
  • Volz MJ, Pleger ST, Weber A, Geis NA, Hamed S, Mereles D, et al. Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis. Eur J Clin Invest [Internet]. 2021;51(6). Available from: https://onlinelibrary.wiley.com/doi/10.1111/eci.13473.
  • Giannini F, Colombo A. Percutaneous treatment of tricuspid valve in refractory right heart failure. Eur Hear J Suppl [Internet]. 2019;21(Supplement_B):B43–7. Available from: https://academic.oup.com/eurheartjsupp/article/21/Supplement_B/B43/5422944.
  • Holmgren G, Steen L, Suhr O, Ericzon B-G, Groth C-G, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet [Internet]. 1993;341(8853):1113–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/014067369393127M.
  • Liepnieks JJ, Zhang LQ, Benson MD. Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology [Internet]. 2010;75(4):324–7. Available from: https://www.neurology.org/doi/10.1212/WNL.0b013e3181ea15d4.
  • Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation [Internet]. 2020;141(15):1214–24. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.045093.
  • Lohrmann G, Pipilas A, Mussinelli R, Gopal DM, Berk JL, Connors LH, et al. Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. J Card Fail [Internet]. 2020;26(9):753–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1071916419314356.
  • Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M. A New Face for Old Antibiotics: Tetracyclines in Treatment of Amyloidoses. J Med Chem [Internet]. 2013;56(15):5987–6006. Available from: https://pubs.acs.org/doi/10.1021/jm400161p.
  • Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med [Internet]. 2018;379(11):1007–16. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1805689.
  • Hammarström P, Schneider F, Kelly JW. Trans -Suppression of Misfolding in an Amyloid Disease. Science (80- ) [Internet]. 2001;293(5539):2459–62. Available from: https://www.science.org/doi/10.1126/science.1062245.
  • Penchala SC, Connelly S, Wang Y, Park MS, Zhao L, Baranczak A, et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci [Internet]. 2013;110(24):9992–7. Available from: https://pnas.org/doi/full/10.1073/pnas.1300761110.
  • Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-Targeted Therapeutics. Cell Metab [Internet]. 2018;27(4):714–39. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1550413118301827.
  • Dasgupta NR, Rissing SM, Smith J, Jung J, Benson MD. Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid [Internet]. 2020;27(1):52–8. Available from: https://www.tandfonline.com/doi/full/10.1080/13506129.2019.1685487.
  • Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med [Internet]. 2018;379(1):22–31. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1716793.
  • Viney NJ, Guo S, Tai L, Baker BF, Aghajan M, Jung SW, et al. Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Hear Fail [Internet]. 2021;8(1):652–61. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ehf2.13154.
  • Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, Berk J, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis [Internet]. 2015;10(1):109. Available from: http://www.ojrd.com/content/10/1/109.
  • Ioannou A, Fontana M, Gillmore JD. Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy. Heart Int [Internet]. 2023;17(1):27. Available from: https://www.touchcardio.com/cardiovascular-disease/journal-articles/patisiran-for-the-treatment-of-transthyretin-mediated-amyloidosis-with-cardiomyopathy/.
  • Solomon SD, Adams D, Kristen A, Grogan M, González-Duarte A, Maurer MS, et al. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation [Internet]. 2019;139(4):431–43. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.035831.
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2021;42(36):3599–726. Available from: https://academic.oup.com/eurheartj/article/42/36/3599/6358045.
  • Rosenblum H, Masri A, Narotsky DL, Goldsmith J, Hamid N, Hahn RT, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail [Internet]. 2021;23(2):250–8. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1974.
  • Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid [Internet]. 2011;18(4):211–5. Available from: http://www.tandfonline.com/doi/full/10.3109/13506129.2011.623199.
  • González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-del Moral FJ, Milandri A, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J [Internet]. 2017;38(24):1895–904. Available from: https://academic.oup.com/eurheartj/article/38/24/1895/3059372.
  • Carroll JD, Gaasch WH, McAdam KPWJ. Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. Am J Cardiol [Internet]. 1982;49(1):9–13. Available from: https://linkinghub.elsevier.com/retrieve/pii/0002914982902703.
  • Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol [Internet]. 2019;26(6):2065–123. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1071358123063900.
  • Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, et al. Echocardiographic findings in systemic amyloidosis: Spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol [Internet]. 1985;6(4):737–43. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109785804757.
  • Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart [Internet]. 2012;98(19):1442–8. Available from: https://heart.bmj.com/lookup/doi/10.1136/heartjnl-2012-302353.
  • Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation [Internet]. 2015;132(16):1570–9. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.115.016567.
  • Holcman K, Kostkiewicz M, Podolec P, Rubiś P. Cardiac amyloidosis-state-of-the-art diagnosis and emerging therapies [in Polish]. Folia Cardiol [Internet]. 2019;14(6):625–33. Available from: https://journals.viamedica.pl/folia_cardiologica/article/view/FC.2019.0115.
  • Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, et al. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Hear Fail [Internet]. 2018;11(2). Available from: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.117.004000.
  • Kapoor M, Foiani M, Heslegrave A, Zetterberg H, Lunn MP, Malaspina A, et al. Plasma neurofilament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst [Internet]. 2019;24(4):314–9. Available from: https://onlinelibrary.wiley.com/doi/10.1111/jns.12350.
  • Holcman K, Kostkiewicz M, Podolec P, Rubiś P. Amyloidoza serca - właściwe rozpoznanie i nowe terapie na horyzoncie [in Polish]. Folia Cardiol [Internet]. 2019;14(6):625–33. Available from: https://journals.viamedica.pl/folia_cardiologica/article/view/67034.
  • Falk RH. Pondering the Prognosis and Pathology of Cardiac Amyloidosis. JACC Cardiovasc Imaging [Internet]. 2016;9(2):139–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X15008633.
  • Perugini E, Guidalotti PL, Salvi F, Cooke RMT, Pettinato C, Riva L, et al. Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. J Am Coll Cardiol [Internet]. 2005;46(6):1076–84. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109705014075.
  • Żelichowski G. Diagnostyka amyloidozy układu sercowo-naczyniowego [in Polish]. Chor Serca i Naczyń [Internet]. 2010;7(1):40–8. Available from: https://journals.viamedica.pl/choroby_serca_i_naczyn/article/view/12024/9902.
  • Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations*. Amyloid [Internet]. 2019;26(1):3–9. Available from: https://www.tandfonline.com/doi/full/10.1080/13506129.2018.1556156.
  • Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99mTc-Pyrophosphate Aid in Early Detection of Cardiac Involvement in Asymptomatic Variant TTR Amyloidosis? JACC Cardiovasc Imaging [Internet]. 2017;10(6):713–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X16304430.
  • Minutoli F, Di Bella G, Mazzeo A, Laudicella R, Gentile L, Russo M, et al. Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation. J Nucl Cardiol [Internet]. 2021;28(5):1949–57. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1071358123015507.
  • Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in Cardiac Amyloidosis: A Review. J Am Heart Assoc [Internet]. 2012;1(2). Available from: https://www.ahajournals.org/doi/10.1161/JAHA.111.000364.
  • Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation [Internet]. 2016;133(24):2404–12. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.116.021612.
  • Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, et al. Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. J Am Coll Cardiol [Internet]. 2008;51(10):1022–30. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109707038727.
  • Pan JA, Kerwin MJ, Salerno M. Native T1 Mapping, Extracellular Volume Mapping, and Late Gadolinium Enhancement in Cardiac Amyloidosis. JACC Cardiovasc Imaging [Internet]. 2020;13(6):1299–310. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X20303041.
  • White JA, Kim HW, Shah D, Fine N, Kim K-Y, Wendell DC, et al. CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis. JACC Cardiovasc Imaging [Internet]. 2014;7(2):143–56. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1936878X13008152.
  • Damrauer SM, Chaudhary K, Cho JH, Liang LW, Argulian E, Chan L, et al. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA [Internet]. 2019 Dec 10;322(22):2191. Available from: https://jamanetwork.com/journals/jama/fullarticle/2757227.
  • Kittleson MM, Maurer MS, Ambardekar A V., Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2020 Jul 7;142(1). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000792.
  • González-Duarte A, Barroso F, Mundayat R, Shapiro B. Blood pressure and orthostatic hypotension as measures of autonomic dysfunction in patients from the transthyretin amyloidosis outcomes survey (THAOS). Auton Neurosci [Internet]. 2019;222:102590. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1566070219301043.
  • Palma J-A, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res [Internet]. 2019;29(S1):33–44. Available from: http://link.springer.com/10.1007/s10286-019-00623-x.
  • Vaishnav J, Hubbard A, Chasler JE, Lepley D, Cuomo K, Riley S, et al. Management of heart failure in cardiac amyloidosis using an ambulatory diuresis clinic. Am Heart J [Internet]. 2021;233:122–31. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002870320304117.
  • Cheng RK, Levy WC, Vasbinder A, Teruya S, De Los Santos J, Leedy D, et al. Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. JACC CardioOncology [Internet]. 2020;2(3):414–24. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2666087320301563.
  • d’Humières T, Fard D, Damy T, Roubille F, Galat A, Doan H-L, et al. Outcome of patients with cardiac amyloidosis admitted to an intensive care unit for acute heart failure. Arch Cardiovasc Dis [Internet]. 2018;111(10):582–90. Available from: https://linkinghub.elsevier.com/retrieve/pii/S187521361830055X.
  • Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet [Internet]. 2011;377(9766):658–66. Available from: https://linkinghub.elsevier.com/retrieve/pii/S187521361830055X.
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J [Internet]. 2023;44(37):3627–39. Available from: https://academic.oup.com/eurheartj/article/44/37/3627/7246292.
  • Finn JD, Smith AR, Patel MC, Shaw L, Youniss MR, van Heteren J, et al. A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. Cell Rep [Internet]. 2018;22(9):2227–35. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211124718301827.
  • George J, Rappaport M, Shimoni S, Goland S, Voldarsky I, Fabricant Y, et al. A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model. Eur Heart J [Internet]. 2020;41(12):1260–70. Available from: https://academic.oup.com/eurheartj/article/41/12/1260/5684841.
  • PRX004, the First Investigational Anti-Amyloid Immunotherapy for the Treatment of ATTR Amyloidosis. 9-month results from a Phase 1 long-term extension study [Internet]. 2020. Available from: https://s201.q4cdn.com/351053094/files/doc_presentations/2020/12/1/PRX004-Phase-1-results-(PDF)-12.8.2020[3].pdf.
  • Garcia-Pavia P, aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen A V., et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med [Internet]. 2023 Jul 20;389(3):239–50. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2303765.
  • Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature [Internet]. 2010;468(7320):93–7. Available from: https://www.nature.com/articles/nature09494.
  • Richards DB, Cookson LM, Berges AC, Barton S V., Lane T, Ritter JM, et al. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med [Internet]. 2015;373(12):1106–14. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1504942.
  • Richards DB, Cookson LM, Barton S V., Liefaard L, Lane T, Hutt DF, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Sci Transl Med [Internet]. 2018;10(422). Available from: https://www.science.org/doi/10.1126/scitranslmed.aan3128.
  • Saelices L, Nguyen BA, Chung K, Wang Y, Ortega A, Lee JH, et al. A pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils. J Biol Chem [Internet]. 2019;294(15):6130–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0021925820366825.
  • Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol [Internet]. 2008;15(6):558–66. Available from: https://www.nature.com/articles/nsmb.1437.
  • Kristen A V., Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol [Internet]. 2012;101(10):805–13. Available from: http://link.springer.com/10.1007/s00392-012-0463-z.
  • Cappelli F, Martone R, Taborchi G, Morini S, Bartolini S, Angelotti P, et al. Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med [Internet]. 2018;13(6):873–80. Available from: http://link.springer.com/10.1007/s11739-018-1887-x.
  • Ferreira N, Saraiva M, Almeida M. Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. Int J Mol Sci [Internet]. 2019;20(6):1287. Available from: https://www.mdpi.com/1422-0067/20/6/1287.

Document Type

Publication order reference

Identifiers

Biblioteka Nauki
33779445

YADDA identifier

bwmeta1.element.ojs-doi-10_31373_ejtcm_189121
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.